139 related articles for article (PubMed ID: 34646246)
1. Development of the Inactivated QazCovid-in Vaccine: Protective Efficacy of the Vaccine in Syrian Hamsters.
Zhugunissov K; Zakarya K; Khairullin B; Orynbayev M; Abduraimov Y; Kassenov M; Sultankulova K; Kerimbayev A; Nurabayev S; Myrzakhmetova B; Nakhanov A; Nurpeisova A; Chervyakova O; Assanzhanova N; Burashev Y; Mambetaliyev M; Azanbekova M; Kopeyev S; Kozhabergenov N; Issabek A; Tuyskanova M; Kutumbetov L
Front Microbiol; 2021; 12():720437. PubMed ID: 34646246
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up.
Khairullin B; Zakarya K; Orynbayev M; Abduraimov Y; Kassenov M; Sarsenbayeva G; Sultankulova K; Chervyakova O; Myrzakhmetova B; Nakhanov A; Nurpeisova A; Zhugunissov K; Assanzhanova N; Nurabayev S; Kerimbayev A; Yershebulov Z; Burashev Y; Kulmagambetov I; Davlyatshin T; Sergeeva M; Buzitskaya Z; Stukova M; Kutumbetov L
EClinicalMedicine; 2022 Aug; 50():101526. PubMed ID: 35770251
[TBL] [Abstract][Full Text] [Related]
3. Absence of Vaccine-enhanced Disease With Unexpected Positive Protection Against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by Inactivated Vaccine Given Within 3 Days of Virus Challenge in Syrian Hamster Model.
Li C; Chen YX; Liu FF; Lee AC; Zhao Y; Ye ZH; Cai JP; Chu H; Zhang RQ; Chan KH; Chiu KH; Lung DC; Sridhar S; Hung IF; To KK; Zhang AJ; Chan JF; Yuen KY
Clin Infect Dis; 2021 Aug; 73(3):e719-e734. PubMed ID: 33515458
[TBL] [Abstract][Full Text] [Related]
4. Development of an Inactivated Camelpox Vaccine from Attenuated Camelpox Virus Strain: Safety and Protection in Camels.
Zhugunissov K; Mambetaliyev M; Sarsenkulova N; Tabys S; Kenzhebaeva M; Issimov A; Abduraimov Y
Animals (Basel); 2023 Apr; 13(9):. PubMed ID: 37174551
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model.
Mohandas S; Yadav PD; Shete-Aich A; Abraham P; Vadrevu KM; Sapkal G; Mote C; Nyayanit D; Gupta N; Srinivas VK; Kadam M; Kumar A; Majumdar T; Jain R; Deshpande G; Patil S; Sarkale P; Patil D; Ella R; Prasad SD; Sharma S; Ella KM; Panda S; Bhargava B
iScience; 2021 Feb; 24(2):102054. PubMed ID: 33521604
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity evaluation of inactivated whole-virus-SARS-COV-2 as emerging vaccine development in Egypt.
Saleh AA; Saad MA; Ryan I; Amin M; Shindy MI; Hassan WA; Samir M; Khattab AA; Abdelgayed SS; Seadawy MG; Fahmy HM; Amer K
Antib Ther; 2021 Jul; 4(3):135-143. PubMed ID: 34286215
[TBL] [Abstract][Full Text] [Related]
7. CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge.
Lien CE; Lin YJ; Chen C; Lian WC; Kuo TY; Campbell JD; Traquina P; Lin MY; Liu LT; Chuang YS; Ko HY; Liao CC; Chen YH; Jan JT; Ma HH; Sun CP; Lin YS; Wu PY; Wang YC; Tao MH; Lin YL
Sci Rep; 2021 Apr; 11(1):8761. PubMed ID: 33888840
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 infection induces protective immunity and limits transmission in Syrian hamsters.
Selvaraj P; Lien CZ; Liu S; Stauft CB; Nunez IA; Hernandez M; Nimako E; Ortega MA; Starost MF; Dennis JU; Wang TT
Life Sci Alliance; 2021 Apr; 4(4):. PubMed ID: 33574037
[TBL] [Abstract][Full Text] [Related]
9. Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease.
van der Lubbe JEM; Rosendahl Huber SK; Vijayan A; Dekking L; van Huizen E; Vreugdenhil J; Choi Y; Baert MRM; Feddes-de Boer K; Izquierdo Gil A; van Heerden M; Dalebout TJ; Myeni SK; Kikkert M; Snijder EJ; de Waal L; Stittelaar KJ; Tolboom JTBM; Serroyen J; Muchene L; van der Fits L; Rutten L; Langedijk JPM; Barouch DH; Schuitemaker H; Zahn RC; Wegmann F
NPJ Vaccines; 2021 Mar; 6(1):39. PubMed ID: 33741993
[TBL] [Abstract][Full Text] [Related]
10. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies.
Kozlovskaya LI; Piniaeva AN; Ignatyev GM; Gordeychuk IV; Volok VP; Rogova YV; Shishova AA; Kovpak AA; Ivin YY; Antonova LP; Mefyod KM; Prokosheva LS; Sibirkina AS; Tarasova YY; Bayurova EO; Gancharova OS; Illarionova VV; Glukhov GS; Sokolova OS; Shaitan KV; Moysenovich AM; Gulyaev SA; Gulyaeva TV; Moroz AV; Gmyl LV; Ipatova EG; Kirpichnikov MP; Egorov AM; Siniugina AA; Ishmukhametov AA
Emerg Microbes Infect; 2021 Dec; 10(1):1790-1806. PubMed ID: 34427172
[TBL] [Abstract][Full Text] [Related]
11. A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters.
Bricker TL; Darling TL; Hassan AO; Harastani HH; Soung A; Jiang X; Dai YN; Zhao H; Adams LJ; Holtzman MJ; Bailey AL; Case JB; Fremont DH; Klein R; Diamond MS; Boon ACM
bioRxiv; 2020 Dec; ():. PubMed ID: 33299991
[TBL] [Abstract][Full Text] [Related]
12. Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy.
Wang Y; Yang C; Song Y; Coleman JR; Stawowczyk M; Tafrova J; Tasker S; Boltz D; Baker R; Garcia L; Seale O; Kushnir A; Wimmer E; Mueller S
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34193524
[TBL] [Abstract][Full Text] [Related]
13. Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2-Infected Syrian Hamsters.
Brocato RL; Principe LM; Kim RK; Zeng X; Williams JA; Liu Y; Li R; Smith JM; Golden JW; Gangemi D; Youssef S; Wang Z; Glanville J; Hooper JW
J Virol; 2020 Oct; 94(22):. PubMed ID: 32900822
[TBL] [Abstract][Full Text] [Related]
14. Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model.
Kurup D; Malherbe DC; Wirblich C; Lambert R; Ronk AJ; Zabihi Diba L; Bukreyev A; Schnell MJ
PLoS Pathog; 2021 Mar; 17(3):e1009383. PubMed ID: 33765062
[TBL] [Abstract][Full Text] [Related]
15. Dataset on safety and protective efficacy studies of COVID-19 vaccine candidates based on structurally modified plant virus in female hamsters.
Kovalenko AO; Ryabchevskaya EM; Evtushenko EA; Kondakova OA; Ivanov PA; Arkhipenko MV; Nikitin NA; Karpova OV
Data Brief; 2023 Jun; 48():109158. PubMed ID: 37095758
[TBL] [Abstract][Full Text] [Related]
16. A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19.
Malherbe DC; Kurup D; Wirblich C; Ronk AJ; Mire C; Kuzmina N; Shaik N; Periasamy S; Hyde MA; Williams JM; Shi PY; Schnell MJ; Bukreyev A
NPJ Vaccines; 2021 Jul; 6(1):91. PubMed ID: 34294728
[TBL] [Abstract][Full Text] [Related]
17. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.
Monath TP; Lee CK; Julander JG; Brown A; Beasley DW; Watts DM; Hayman E; Guertin P; Makowiecki J; Crowell J; Levesque P; Bowick GC; Morin M; Fowler E; Trent DW
Vaccine; 2010 May; 28(22):3827-40. PubMed ID: 20347059
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies.
Kandeil A; Mostafa A; Hegazy RR; El-Shesheny R; El Taweel A; Gomaa MR; Shehata M; Elbaset MA; Kayed AE; Mahmoud SH; Moatasim Y; Kutkat O; Yassen NN; Shabana ME; GabAllah M; Kamel MN; Abo Shama NM; El Sayes M; Ahmed AN; Elalfy ZS; Mohamed BM; Abd El-Fattah SN; El Hariri HM; Abdel Kader M; Azmy O; Kayali G; Ali MA
Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33802467
[TBL] [Abstract][Full Text] [Related]
19. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
[TBL] [Abstract][Full Text] [Related]
20. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
